Patents by Inventor Michael S. German
Michael S. German has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8193330Abstract: The present invention features polypeptides having activity of human neurogenin3 (hNgn3), and nucleic acid encoding such polypeptide. The invention also features use of islet transcription factors such as hNgn3 to facilitate production of pancreatic islet cells from progenitor cells, and to facilitate insulin delivery by production of islet cells so produced.Type: GrantFiled: August 14, 2003Date of Patent: June 5, 2012Assignee: The Regents of the University of CaliforniaInventor: Michael S. German
-
Patent number: 7323165Abstract: The present invention relates to the production of islet cells and insulin in a subject by providing for expression of an islet transcription factors in the pancreas of the subject, by for example, introduction of nucleic acid encoding the transcription factor neurogenin3 or a factor that induces neuorgenin3 expression. The present invention also relates to methods for using a islet transcription factor gene and the islet transcription factor polypeptide to alter cellular differentiation in culture or in vivo to produce new ?-cells to treat patients with diabetes mellitus.Type: GrantFiled: March 4, 2004Date of Patent: January 29, 2008Assignee: The Regents of the University of CaliforniaInventor: Michael S. German
-
Patent number: 6967019Abstract: The present invention relates to the production of islet cells and insulin in a subject by providing for expression of an islet transcription factors in the pancreas of the subject, by for example, introduction of nucleic acid encoding the transcription factor neurogenin3 or a factor that induces neuorgenin3 expression. The present invention also relates to methods for using a islet transcription factor gene and the islet transcription factor polypeptide to alter cellular differentiation in culture or in vivo to produce new ?-cells to treat patients with diabetes mellitus.Type: GrantFiled: March 20, 2001Date of Patent: November 22, 2005Assignee: The Regents of the University of CaliforniaInventor: Michael S. German
-
Publication number: 20040152168Abstract: The present invention features polypeptides having activity of human neurogenin3 (hNgn3), and nucleic acid encoding such polypeptide. The invention also features use of islet transcription factors such as hNgn3 to facilitate production of pancreatic islet cells from progenitor cells, and to facilitate insulin delivery by production of islet cells so produced.Type: ApplicationFiled: March 3, 2004Publication date: August 5, 2004Inventor: Michael S. German
-
Publication number: 20040142901Abstract: The present invention relates to the production of islet cells and insulin in a subject by providing for expression of an islet transcription factors in the pancreas of the subject, by for example, introduction of nucleic acid encoding the transcription factor neurogenin3 or a factor that induces neuorgenin3 expression. The present invention also relates to methods for using a islet transcription factor gene and the islet transcription factor polypeptide to alter cellular differentiation in culture or in vivo to produce new &bgr;-cells to treat patients with diabetes mellitus.Type: ApplicationFiled: March 4, 2004Publication date: July 22, 2004Inventor: Michael S. German
-
Publication number: 20040127448Abstract: The invention features methods for delivering a polypeptide to the bloodstream of a subject by introduction of a nucleic acid construct into secretory gland cells (e.g., cells of salivary gland, pancreas, or liver). In general, the method involves introduction of a nucleic acid construct into a secretory gland duct, which introduction results in expression of a gene product encoded by the introduced construct and delivery of the gene product into the bloodstream of the subject.Type: ApplicationFiled: December 11, 2003Publication date: July 1, 2004Applicant: The Regents of The University of CaliforniaInventors: Michael S. German, Ira D. Goldfine, Stephen S. Rothman
-
Publication number: 20040106555Abstract: The present invention features polypeptides having activity of human neurogenin3 (hNgn3), and nucleic acid encoding such polypeptide. The invention also features use of islet transcription factors such as hNgn3 to facilitate production of pancreatic islet cells from progenitor cells, and to facilitate insulin delivery by production of islet cells so produced.Type: ApplicationFiled: August 14, 2003Publication date: June 3, 2004Inventor: Michael S. German
-
Patent number: 6703220Abstract: The present invention features a human neurogenin3 (Ngn3) polypeptide and nucleotide sequences encoding Ngn3 polypeptides. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:1. In addition, the invention features isolated nucleic acid sequence comprising an Ngn3 promoter, as well as a polynucleotide sequences that hybridize under stringent conditions to SEQ ID NO:1. In related aspects the invention features expression vectors and host cells comprising polynucleotides that encode a human Ngn3 polypeptide.Type: GrantFiled: March 24, 2000Date of Patent: March 9, 2004Assignee: The Regents of the University of CaliforniaInventors: Michael S. German, Joseph Lin
-
Publication number: 20030078226Abstract: The invention features methods for delivering a polypeptide to the bloodstream of a subject by introduction of a nucleic acid construct into secretory gland cells(e.g., cells of salivary gland, pancreas, or liver). In general, the method involves introduction of a nucleic acid construct into a secretory gland duct, which introduction results in expression of a gene product encoded by the introduced construct and delivery of the gene product into the bloodstream of the subject.Type: ApplicationFiled: June 14, 2002Publication date: April 24, 2003Inventors: Michael S. German, Ira D. Goldfine, Stephen S. Rothman
-
Patent number: 6531455Abstract: The invention features methods for delivering a polypeptide to the bloodstream of a subject by introduction of a nucleic acid construct into secretory gland cells(e.g., cells of salivary gland, pancreas, or liver). In general, the method involves introduction of a nucleic acid construct into a secretory gland duct, which introduction results in expression of a gene product encoded by the introduced construct and delivery of the gene product into the bloodstream of the subject.Type: GrantFiled: April 14, 2000Date of Patent: March 11, 2003Assignee: The Regents of the University of CaliforniaInventors: Michael S. German, Ira D. Goldfine, Stephen S. Rothman
-
Patent number: 6436667Abstract: The present invention features a human Nkx-6.1 polypeptide and nucleotide sequences encoding Nkx-6.1 polypeptides. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:1. In addition, the invention features polynucleotide sequences that hybridize under stringent conditions to SEQ ID NO:1. In related aspects the invention features expression vectors and host cells comprising polynucleotides that encode a human Nkx-6.1 polypeptide. The present invention also relates to antibodies that bind specifically to a human Nkx-6.1 polypeptide, and methods for producing human Nkx-6.1 polypeptides.Type: GrantFiled: January 20, 1998Date of Patent: August 20, 2002Assignees: The Regents of the University of California, Washington UniversityInventors: Michael S. German, M. Alan Permutt, Hiroshi Inoue
-
Publication number: 20020015696Abstract: The present invention relates to the production of islet cells and insulin in a subject by providing for expression of an islet transcription factors in the pancreas of the subject, by for example, introduction of nucleic acid encoding the transcription factor neurogenin3 or a factor that induces neuorgenin3 expression. The present invention also relates to methods for using a islet transcription factor gene and the islet transcription factor polypeptide to alter cellular differentiation in culture or in vivo to produce new &bgr;-cells to treat patients with diabetes mellitus.Type: ApplicationFiled: March 20, 2001Publication date: February 7, 2002Inventor: Michael S. German
-
Patent number: 6239258Abstract: The present invention features a human Nkx-2.2 polypeptide and nucleotide sequences encoding Nkx-2.2 polypeptides. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:1. In addition, the invention features polynucleotide sequences that hybridize under stringent conditions to SEQ ID NO:1. In related aspects the invention features expression vectors and host cells comprising polynucleotides that encode a human Nkx-2.2 polypeptide. The present invention also relates to antibodies that bind specifically to a human Nkx-2.2 polypeptide, and methods for producing human Nkx-2.2 polypeptides.Type: GrantFiled: January 20, 1998Date of Patent: May 29, 2001Assignees: The Regents of the University of California, Arch Development Corp.Inventors: Michael S. German, Graeme I. Bell, Hiroto Furuta, Lori Sussel
-
Patent number: 6127598Abstract: The present invention features mouse models for Nkx-2.2 gene function and for Nkx-6.1 gene function, wherein the transgenic mouse is characterized by having a defect in Nkx-2.2 gene function or a defect in Nkx-6.1 gene function (where, because Nkx-2.2 acts upstream of Nkx-6.1, a defect in Nkx-2.2 gene function affects Nkx-6.1 gene function) and by having a decreased number of insulin-producing cells relative to a normal mouse. Where the transgenic mouse contains a defect in Nkx-2.2 gene function, the mouse is further characterized by a decreased number of serotonin-producing cells relative to a normal mouse. The transgenic mice may be either homozygous or heterozygous for the Nkx-2.2 or Nkx-6.1 defect.Type: GrantFiled: July 25, 1997Date of Patent: October 3, 2000Assignee: The Regents of the University of CaliforniaInventors: Michael S. German, John L.R. Rubenstein, Lori Sussel, Maike Sander, Dennis J. Hartigan-O'Connor, Roger A. Pedersen, Juanito J. Meneses
-
Patent number: 6004944Abstract: Secretory gland cells, particularly pancreatic, hepatic, and salivary gland cells, are genetically altered to operatively incorporate a gene which expresses a protein which has a desired therapeutic effect on a mammalian subject. The expressed protein is secreted directly into the bloodstream to obtain therapeutic levels of the protein thereby treating the patient in need of the protein. The transformed secretory gland cells provide long term or short term therapies for diseases associated with a deficiency in a particular protein or which are amenable to treatment by overexpression of a protein.Type: GrantFiled: October 2, 1997Date of Patent: December 21, 1999Assignee: The Regents of the University of CaliforniaInventors: Stephen S. Rothman, Ira D. Goldfine, Michael S. German
-
Patent number: 5830730Abstract: A composition for transfecting eukaryotic cells comprising a cationic polymer which has protonatable groups which serve to buffer the acidic endosome, protecting the endocytosed polynucleotide from degradation and a viral agent is used to target uptake into and/or lysis from endosomes in the desired eukaryotic cell. By co-infecting the eukaryotic cells with cationic polymer, polynucleotide, and the viral agent, the polynucleotide is brought into the cell and then released. Preferably, polyamidoamine dendrimers are used as the cationic polymer and adenovirus is used as the viral agent. The dendrimers help associate plasmid DNA with the adenovirus, which then provokes receptor-mediated endocytosis. Within the endosome, the tertiary amine groups of the dendrimer buffer the pH change in the endosome. Then, the endosomalytic activity of the adenovirus releases the plasmid DNA into the cell.Type: GrantFiled: May 8, 1997Date of Patent: November 3, 1998Assignee: The Regents of the University of CaliforniaInventors: Michael S. German, Francis C. Szoka, Jr.